Search Results - "Viassolo, V"

BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients by Friedlaender, A., Vuillemier, A., Viassolo, V., Ayme, A., De Talhouet, S., Combes, J.-D., Peron, J., Bodmer, A., Giraud, S., Buisson, A., Bonadona, V., Gauchat-Bouchardy, I., Tredan, O., Chappuis, P., Labidi-Galy, S.I.

Get full text

Performance of BOADICEA and BRCAPRO genetic models and of empirical criteria based on cancer family history for predicting BRCA mutation carrier probabilities: A retrospective study in a sample of Italian cancer genetics clinics by Varesco, L, Viassolo, V, Viel, A, Gismondi, V, Radice, P, Montagna, M, Alducci, E, Della Puppa, L, Oliani, C, Tommasi, S, Caligo, M.A, Vivanet, C, Zuradelli, M, Mandich, P, Tibiletti, M.G, Cavalli, P, Lucci Cordisco, E, Turchetti, D, Boggiani, D, Bracci, R, Bruzzi, P, Bonelli, L

“…Abstract Purpose To evaluate in current practice the performance of BOADICEA and BRCAPRO risk models and empirical criteria based on cancer family history for…”
Get full text

Inclusion body myopathy, Paget's disease of the bone and frontotemporal dementia: recurrence of the VCP R155H mutation in an Italian family and implications for genetic counselling by Viassolo, V, Previtali, SC, Schiatti, E, Magnani, G, Minetti, C, Zara, F, Grasso, M, Dagna-Bricarelli, F, Di Maria, E

“…The acronym IBMPFD denotes a syndrome including inclusion body myopathy, Paget’s disease of the bone (PDB) and frontotemporal dementia (FTD) as cardinal…”
Get full text

A familial case of achondrogenesis type II caused by a dominant COL2A1 mutation and “patchy” expression in the mosaic father by Forzano, F., Lituania, M., Viassolo, A., Superti‐Furga, V., Wildhardt, G., Zabel, B., Faravelli, F.

“…Achondrogenesis type II (ACG2) is the most severe disorder that can be produced by dominant mutations in COL2A1. We report on four pregnancies of an apparently…”
Get full text

Prenatal diagnosis of Gollop-Wolfgang Complex by Forzano, Francesca, Viassolo, V., Castagnetta, M., Cavani, S., Battistuzzi, L., Garbati, E., Emiliozzi, M.C., Cecchi, A., Faravelli, F., Lituania, M.

Get full text

238PBRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients by Friedlaender, A, Vuillemier, A, Viassolo, V, Ayme, A, De Talhouet, S, Combes, J-D, Peron, J, Bodmer, A, Giraud, S, Buisson, A, Bonadona, V, Gauchat-Bouchardy, I, Tredan, O, Chappuis, P, Labidi-Galy, S I

Get full text

1003P - Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers by Labidi-Galy, S.I., deLa Motte Rouge, T., Derbel, O., Wolfer, A., Kalbacher, E., Olivier, T., Combes, J.-D., Hu-Heimgartner, K., Tredan, O., Guevara, H., Heinzelmann-Schwarz, V., Fehr, M., de Castelbajac, V., Vaflard, P., Crivelli, L., Bonadona, V., Viassolo, V., Bazan, F., Rodrigues, M., Ray-Coquard, I.L.

“…To investigate clinical factors associated with prolonged progression-free survival (PFS) and overall survival (OS) in relapsing epithelial ovarian cancer…”
Get full text

Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers by Labidi-Galy, S.I., deLa Motte Rouge, T., Derbel, O., Wolfer, A., Kalbacher, E., Olivier, T., Combes, J.-D., Hu-Heimgartner, K., Tredan, O., Guevara, H., Heinzelmann-Schwarz, V., Fehr, M., de Castelbajac, V., Vaflard, P., Crivelli, L., Bonadona, V., Viassolo, V., Bazan, F., Rodrigues, M., Ray-Coquard, I.L.

Get full text

1003PClinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers by Labidi-Galy, S I, de, T, Rouge, La Motte, Derbel, O, Wolfer, A, Kalbacher, E, Olivier, T, Combes, J-D, Hu-Heimgartner, K, Tredan, O, Guevara, H, Heinzelmann-Schwarz, V, Fehr, M, de Castelbajac, V, Vaflard, P, Crivelli, L, Bonadona, V, Viassolo, V, Bazan, F, Rodrigues, M, Ray-Coquard, I L

“…Abstract Background To investigate clinical factors associated with prolonged progression-free survival (PFS) and overall survival (OS) in relapsing epithelial…”
Get full text

Abstract P3-03-05: Association between BRCA1 and BRCA2 mutations and survival in breast cancer patients according to molecular subtype by Tredan, O, De Talhouet, S, Peron, J, Friedlaender, A, Vuilleumier, A, Viassolo, V, Ayme, A, Chappuis, PO, Buisson, A, Bonadona, V, Bodmer, A, Labidi-Galy, SI

“…Abstract Background: Germline mutations in BRCA1/BRCA2 genes increase the risk of breast and ovarian cancers. In ovarian cancer patients (pts) treated with…”
Get full text

Location of mutation in BRCA2 gene and survival in patients with ovarian cancer by Labidi-Galy, S.I., Olivier, T., Rodrigues, M., Ferraioli, D., Derbel, O., Bodmer, A., Petignat, P., Chopin, N., Tredan, O., Heudel, P., Viassolo, V., Ayme, A., Chappuis, P.O., Stern, M-H., Houdayer, C., Stoppa-Lyonnet, D., Buisson, A., Golmard, L., Bonadona, V., Ray-Coquard, I.

Get full text

Prognostic significance of BRCA1, PARP1, and PARP2 in sporadic breast cancer by Gennari, A., Sormani, M., Varesco, L., Pronzato, P., Viassolo, V., Mirisola, V., Pfeffer, U., Bruzzi, P.

“…Abstract only e22114 Background: Breast cancer susceptibility gene (BRCA1) is a tumor suppressor gene whose mutation is associated with the development of…”
Get full text

Prenatal diagnosis of Gollop-Wolfgang Complex by zano, Francesca, Viassolo, V, Castagnetta, M, Cavani, S, Battistuzzi, L, Garbati, E, Emiliozzi, M C, Cecchi, A, Faravelli, F, Lituania, M

Get full text